Puma Biotechnology Inc (PBYI) Stock

About Puma Biotechnology Inc

Puma Biotechnology Inc is led by CEO Alan H. Auerbach, employs 172 people, headquartered in US, publicly traded since 2012.

Puma Biotechnology Inc (PBYI) stock trades at $11.02 with a market capitalization of $568.85M. The stock is valued at a price-to-earnings (P/E) ratio of 17.55, price-to-book of 3.46, price-to-sales of 1.30. Over the past 52 weeks the stock has ranged between $4.58 and $11.27, and currently trades 2.2% below its 52-week high.

On profitability, Puma Biotechnology Inc generates a return on equity (ROE) of 20.85%, above the typical market range of roughly 12-15%, return on capital employed of 27.41%, an operating margin of 16.23%, a net profit margin of 13.62%.

Puma Biotechnology Inc by the numbers, 2016–2025

Between 2016 and 2025 Puma Biotechnology Inc reported revenue of $0 rising to $228.0M. Compounded, revenue has grown 0.3% a year over five years, 0.0% over three, -0.9% over the last twelve months. Net profit rose to $31.0M.

The most recent net margin is 13.62%. On a trailing twelve-month basis to Jun '26, revenue is $231.0M and net profit $26.0M.

Borrowings stand at $29.0M, cash from operations was $42.0M in the latest year, positive in 6 of the last 10.

Return on equity has averaged 309.6% over five years, and was 23.9% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Puma Biotechnology Inc (PBYI) — frequently asked questions